Genelux Corporation

NASDAQ:GNLX

Biotechnology

Healthcare
$2.24 +2.63%

+$0.08 today

Market cap
$107.66M
Beta
0.55
P/E (TTM)
-3.0
EPS (TTM)
-$0.98
52W Low $2.29High $8.54

Volume 0.80M

Average 0.19M

GNLX Stock-Based Compensation

Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.

Genelux CorporationNASDAQ: GNLX

Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026

Stock-based compensation dips below year-ago levels

Q1 FY2026 stock-based compensation of $1.39M fell 2.4% year over year, behind the +8.8% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 72.1% from the prior quarter. Over 3 fiscal years it compounded at +34.5% a year.

Context

  • Stock-based compensation amounted to 73387.5% of revenue in FY2025, down 2487.5 pp from a year earlier.
  • Stock-based compensation increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -2.4% toward the trailing-twelve-month pace of +8.8%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.39M+72.1% QoQ
Last fiscal yearDec 2025
$5.87M-3.3% YoY
LTMMar 2026
$5.84M+8.8% YoY
Stock-Based Compensation past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.4%——
1 year-3.3%——
3-year CAGR+34.5%——
5-year CAGR——
10-year CAGR——

Stock-Based Compensation history

USD · from the cash flow

Latest · FY2025
5.87M USD
Year-over-year change
-3.3%
4-year CAGR
+8.3%

Stock-Based Compensation vs competitors

How GNLX compares with its peers on the latest reported figures

  • Peers report in different currencies, so stock-based compensation is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +8.8% is the 3rd highest of 9, against a peer median of -14.1%.
  • Stock-based compensation amounts to 72950.0% of revenue for GNLX, versus a peer median of 1385.0%.
GNLX Competitors
Stock-Based Compensation for GNLX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
LYELLyell Immunopharma, Inc.LTM Mar 2026$35.81M USD+19.3%—115500.0%
SLNSilence Therapeutics plcLTM Mar 2026$14.34M USD—-14.0%1556.3%
CTNMContineum Therapeutics, Inc. Class A Common StockLTM Mar 2026$11.29M USD+31.2%+73.3%—
LXEOLexeo Therapeutics, Inc. Common StockLTM Mar 2026$11.19M USD-19.1%+89.6%—
MREOMereo BioPharma Group plcLTM Mar 2026$6.93M USD-9.1%+16.8%1385.0%
GNLXGenelux CorporationLTM Mar 2026$5.84M USD+8.8%+34.5%72950.0%
CADLCandel Therapeutics, Inc.LTM Mar 2026$4.96M USD+8.1%+18.3%—
ALDXAldeyra Therapeutics, Inc.LTM Mar 2026$2.88M USD-66.7%-9.8%—
ACIUAC Immune S.A.LTM Dec 2025CHF 2.68M CHF-42.8%—75.0%
CLLSCellectis S.A.LTM Mar 2026$1.28M USD-60.6%—1.9%
DRTSAlpha Tau Medical Ltd.LTM Dec 2025$0 USD———
Peer median (excluding GNLX) —-14.1%+17.5%1385.0%

Competitors are the stored peer set for GNLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(16.38M)(5.21M)(28.3M)(29.87M)(32.15M)
Depreciation & Amortization895K968K1.02M903K244K
Deferred Income Tax348K0000
Stock-Based Compensation4.27M2.42M5.2M6.07M5.87M
Change in Working Capital4.08M(1.69M)(3.28M)751K(1.05M)
Accounts Receivables00000
Inventory00000
Accounts Payables754K2.31M(2.36M)2.16M(1.21M)
Other Working Capital3.33M(4M)(923K)(1.41M)167K
Other Non-Cash Items196K(56K)5.08M917K1.81M
Operating Cash Flow(6.59M)(3.57M)(20.28M)(21.23M)(25.27M)
Capital Expenditures0(49K)(1.03M)(381K)(1.1M)
Acquisitions (Net)00000
Purchases of Investments00(13.7M)(29M)(18.26M)
Sales of Investments00021.25M31.5M
Other Investing Activities00000
Investing Cash Flow0(49K)(14.72M)(8.13M)12.14M
Debt Repayment(558K)970K215K00
Common Stock Issued143K120K39.65M27.82M9.9M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities145K(1.45M)4.16M688K0
Financing Cash Flow(270K)(478K)44.02M28.51M9.9M
Effect of Forex Changes00000
Net Change in Cash(6.86M)(4.1M)9.02M(853K)(3.23M)
Free Cash Flow(6.59M)(3.62M)(21.3M)(21.61M)(26.37M)

Genelux Corporation

NASDAQ:GNLX

Intrinsic Alpha fair value

Locked

Current Price

$2.24

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.